How cancer immunotherapy is transforming canine oncology, offering new welfare-positive treatment options that differ fundamentally from conventional chemotherapy in their side effect profiles.
Cancer immunotherapy represents a welfare advance in canine oncology through its fundamentally different side effect profile compared to conventional chemotherapy. While immunotherapy is not without adverse effects — immune-related inflammatory responses can be serious — the absence of severe nausea, profound myelosuppression, and the debilitating fatigue associated with conventional chemotherapy represents a meaningful welfare improvement for many cancer types where immunotherapy is effective. The comparative oncology model — where dogs with naturally occurring cancer access experimental treatments in clinical trials — creates a mutually beneficial arrangement: dogs access potentially life-extending treatments while contributing to knowledge that benefits both canine and human cancer patients.